Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors.
Marina DanilenkoWolfson Childhood Cancer Research Centre, Translational & Clinical Research Institute, Newcastle University Centre for Cancer, Herschel Building, Newcastle upon Tyne NE1 7RU, UK.ORCID 0009-0007-1227-8674
Sharanya NathWolfson Childhood Cancer Research Centre, Translational & Clinical Research Institute, Newcastle University Centre for Cancer, Herschel Building, Newcastle upon Tyne NE1 7RU, UK.ORCID 0000-0002-8785-8530
Jack BainesNewcastle Genetics Lab., Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE1 4EP, UK.ORCID 0000-0002-8593-3998
Freya GordonWolfson Childhood Cancer Research Centre, Translational & Clinical Research Institute, Newcastle University Centre for Cancer, Herschel Building, Newcastle upon Tyne NE1 7RU, UK.
Swathi MeruguWolfson Childhood Cancer Research Centre, Translational & Clinical Research Institute, Newcastle University Centre for Cancer, Herschel Building, Newcastle upon Tyne NE1 7RU, UK.
Lisa M AllinsonWolfson Childhood Cancer Research Centre, Translational & Clinical Research Institute, Newcastle University Centre for Cancer, Herschel Building, Newcastle upon Tyne NE1 7RU, UK.ORCID 0000-0002-8957-6609
Aaron PottsNewcastle Genetics Lab., Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE1 4EP, UK.
Bethany CollinsNewcastle Genetics Lab., Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE1 4EP, UK.
Angharad GoodmanNewcastle Genetics Lab., Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE1 4EP, UK.ORCID 0000-0002-3010-5757
Samuel E KidmanNewcastle Genetics Lab., Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE1 4EP, UK.
Ciaron McAnultyNewcastle Genetics Lab., Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE1 4EP, UK.
David JamiesonTranslational & Clinical Research Institute, Newcastle University Centre for Cancer, Paul O'Gorman Building, Newcastle upon Tyne NE2 4HH, UK.ORCID 0000-0002-3064-6713
Deborah A TweddleWolfson Childhood Cancer Research Centre, Translational & Clinical Research Institute, Newcastle University Centre for Cancer, Herschel Building, Newcastle upon Tyne NE1 7RU, UK.ORCID 0000-0003-2208-3970
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Blood Cancer UK CRCPSC-Dec21\100002Cancer Research UK CRCPSC-Dec21\100002Cancer Research UK CTQQR-2021\100003Little Princess Trust CCLGA 2016 08NCI NIH HHS P30 CA008748
6 · The paper itself
Abstract
Neuroblastoma (NB) is an aggressive childhood cancer requiring intensive multimodal therapies in high-risk (HRNB) patients. Currently, invasive surgical biopsies are required to classify NB risk group and assign treatment based on the tumour genetic profile. Circulating tumour DNA (ctDNA) obtained from blood samples can be used to identify tumour biomarkers. Here we applied targeted next-generation sequencing (tNGS) using a panel of 42 genes to analyse 32 NB ctDNA samples for the presence of single-nucleotide variants and copy number changes from 28 patients in all NB risk groups. In two additional ctDNA samples, droplet digital PCR was used to detect hotspot
Indexed as
Biomarkers, TumorCirculating Tumor DNANeuroblastomaAnaplastic Lymphoma KinaseChildChild, PreschoolDNA Copy Number VariationsFemaleGene FrequencyHigh-Throughput Nucleotide SequencingHumansInfantMaleMutationPolymorphism, Single NucleotideProtein Tyrosine Phosphatase, Non-Receptor Type 11ALK protein, humanAnaplastic Lymphoma KinaseBiomarkers, TumorCirculating Tumor DNAProtein Tyrosine Phosphatase, Non-Receptor Type 11PTPN11 protein, humancirculating tumour DNAddPCRliquid biopsyneuroblastomanext-generation sequencingpaediatric cancer
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Detection of Targetable Genetic Abnormalities in Neuroblastoma Circulating Tumour DNA. · full record | OpenQuestion